You can now read 10 articles each month for free on BostonGlobe.com.

The Boston Globe

Business

Jazz Pharmaceuticals

Continue reading below

The maker of the narcolepsy medicine Xyrem rose on its deal to buy EUSA Pharma Inc. for $650 million to diversify its drug holdings, including a therapy for leukemia. Acquiring closely held EUSA, based in Langhorne, Pa., will immediately add to earnings, Dublin-based Jazz said, and increase 2013 revenue by $210 million to $230 million. EUSA posted first-quarter net sales of $46 million.

You have reached the limit of 10 free articles a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than $1 a week